Close Menu

NEW YORK – Natera reported after the close of the market on Wednesday that its second quarter revenues grew 16 percent year over year, driven by sales of its Panorama noninvasive prenatal and Horizon carrier screening tests.

For the three months ended June 30, Natera had $86.5 million in revenues, up from $74.4 million a year ago and beating the average Wall Street estimate of $73.1 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.